Psychedelic Legal Status by State: A Plain-English Overview

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

Who this is for: Anyone who wants a current, accurate reference for where psychedelics — particularly psilocybin — stand legally across the United States. This article covers state-level status only. Federal law prohibits all classical psychedelics under the Controlled Substances Act regardless of what any state or city has done. The federal layer applies everywhere.

A note on accuracy: Psychedelic law is changing faster than almost any other area of drug policy. This article reflects the status as of early 2026. Before making any decision based on what follows, verify the current law in your jurisdiction.

How to read this article

States appear in four tiers based on their current legal posture: (1) states with active licensed access programs, (2) states with statewide decriminalization, (3) states with city-level decriminalization only, and (4) states that are prohibited but have passed study commissions, working groups, or significant pending legislation. States with no relevant reform appear in a final summary.

Within each tier, federal law still applies. No state tier represents federal legality.

Tier 1: States with licensed regulated access programs

These three states have enacted state-law frameworks authorizing supervised access to psilocybin through licensed facilities, without requiring a clinical trial or FDA authorization. Federal law still classifies psilocybin as Schedule I in all three.

Oregon

Oregon was the first state to create a regulated psilocybin access program, through Ballot Measure 109 approved by voters in November 2020. The Oregon Health Authority (OHA) licenses service centers, facilitators, manufacturers, and testing laboratories. Adults 21 and older — including non-residents — may access psilocybin services at a licensed service center through a licensed facilitator, without a prescription or diagnosis. Service centers began accepting clients in summer 2023.

Key features: no residency requirement for clients; no medical diagnosis required; facilitators do not need to be licensed mental health professionals (though a clinical facilitator track exists); sessions must occur on-site at the licensed center; psilocybin cannot be taken home. The OHA publishes a public directory of licensed service centers.

In May 2025, Governor Tina Kotek signed HB 2387, which allows licensed medical and mental health professionals to provide psilocybin services within their existing practices under a clinical facilitator track, aligning Oregon more closely with Colorado’s model. The clinical facilitator provisions took effect January 1, 2026.

Colorado

Colorado’s Natural Medicine Health Act (Proposition 122) was approved by voters in November 2022. The program is split between two agencies: the Department of Regulatory Agencies (DORA) oversees facilitator licensing, and the Department of Revenue (DOR) oversees business licensing for healing centers, cultivators, manufacturers, and testing facilities. Licensed healing centers began operating in 2025.

Two features distinguish Colorado from Oregon. First, Proposition 122 separately decriminalized personal use, possession, and cultivation of psilocybin, psilocin, ibogaine, DMT, and mescaline (excluding peyote) for adults 21 and older outside any licensed program — meaning personal use in private is decriminalized even without a licensed facility. Second, Colorado’s program includes a micro-healing center track for licensed mental and medical health professionals who want to integrate psilocybin into their existing practices.

The licensed program currently covers psilocybin and psilocin only. DMT, ibogaine, and mescaline may be added to the licensed program on or after June 1, 2026, if recommended by the Natural Medicine Advisory Board.

New Mexico

New Mexico became the third state to create a legal access pathway for psilocybin when Governor Michelle Lujan Grisham signed Senate Bill 219, the Medical Psilocybin Act, on April 7, 2025. The law took effect June 20, 2025. New Mexico is the first state to accomplish this through legislation rather than ballot initiative.

New Mexico’s program is more medically structured than Oregon or Colorado. Psilocybin must be administered by a licensed healthcare provider in an approved setting to a patient with a qualifying medical condition. Current qualifying conditions are: major treatment-resistant depression, PTSD, substance use disorders, and end-of-life care. The Department of Health may add conditions over time.

The program does not include a personal use decriminalization component. There is no take-home access. The program must be fully implemented by December 31, 2027, though the Department of Health announced in December 2025 a goal of accepting initial patients by end of 2026. Unlike Oregon and Colorado, New Mexico’s program covers naturally occurring psilocybin only — synthetic psilocybin and its analogs are expressly excluded.

Tier 2: States with statewide personal use decriminalization (without a licensed program)

No state currently sits in this tier in isolation. Colorado’s decriminalization is paired with its licensed program. Oregon decriminalized possession of all drugs statewide through Measure 110 in 2020, but that measure was largely repealed by the legislature in 2024. As of early 2026, no state has enacted a standalone statewide decriminalization of psilocybin without also creating a licensed access program.

Tier 3: States with city-level decriminalization only

In these states, psilocybin remains illegal under state law. Specific cities or counties have passed resolutions or ordinances directing local law enforcement to deprioritize enforcement of personal possession. State law, state enforcement agencies, and federal law remain unchanged.

California

California has no statewide decriminalization of psilocybin. SB 58, which would have decriminalized personal possession of psilocybin and other natural psychedelics for adults 21 and older, passed the legislature in 2023 but was vetoed by Governor Newsom in October 2023. He cited the absence of therapeutic guidelines and urged the legislature to return with legislation that includes a treatment framework.

Cities with local deprioritization measures include Oakland (June 2019, covers psilocybin mushrooms, peyote, iboga, ayahuasca), Santa Cruz (January 2020), and San Francisco (September 2022, covering entheogens broadly). These measures direct local law enforcement not to spend resources on enforcement of personal possession. State law and state enforcement agencies are unaffected.

Michigan

No statewide decriminalization. Cities with deprioritization measures include Ann Arbor (September 2020), Detroit (November 2021, approved by voters), and Hazel Park (March 2022). Washtenaw County, which includes Ann Arbor, extended its measure county-wide in January 2021.

Washington

No statewide decriminalization of psilocybin. Seattle passed a unanimous council resolution in October 2021 covering psilocybin mushrooms, ayahuasca, ibogaine, and non-peyote mescaline. Port Townsend passed a similar resolution in December 2021. Olympia decriminalized plant-based hallucinogens in August 2024. Tacoma decriminalized natural psychedelics in January 2025. King County voted to deprioritize personal psychedelic use in March 2026.

Massachusetts

No statewide decriminalization. A statewide ballot initiative was rejected by voters in November 2024, with 57.1% voting no. Cities with personal possession deprioritization measures include Somerville (January 2021), Cambridge (February 2021), Northampton (March 2021), and Easthampton (October 2021).

Washington, D.C.

Voters approved a ballot measure in November 2020 deprioritizing enforcement of laws criminalizing entheogenic plants and fungi. The D.C. measure covers personal possession and use of entheogenic plants including psilocybin. Commercial sale remains illegal.

Tier 4: States with study commissions, research pilots, or active pending legislation — but prohibited

These states have taken no decriminalization action but have established formal working groups, appropriated research funding, or passed legislation establishing frameworks preparatory to potential access.

Alaska: HB 228 became law in 2024, establishing a task force to prepare policy recommendations for potential medicalization of psychedelics, including on licensing, insurance, and implementation.

Arizona: The state legislature passed a rescheduling trigger bill in 2025, and Arizona’s FY2026 budget earmarked $5 million for ibogaine research. Discussed separately in Article 7 (ibogaine and mescaline).

Connecticut: HB 7065, which would have removed jail time for personal possession of up to half an ounce of psilocybin (replacing it with a $150 fine), passed the House in 2025 but did not advance in the Senate before the legislature adjourned.

Hawaii: SB 1042 would establish a pilot program to study psychedelic therapies including psilocybin and MDMA. The bill passed the House with amendments in 2025 and was under Senate consideration. HB 1034, which would have decriminalized personal possession of psilocybin, was tabled in the House in June 2025.

Texas: SB 2308, signed by Governor Abbott in June 2025, appropriated $50 million for clinical trials studying pharmaceutical applications of ibogaine. Texas has separately appropriated research funds for psilocybin studies. Texas remains prohibitionist on personal possession.

Vermont: A working group has been established to review the therapeutic use of psychedelics and make legislative recommendations. Decriminalization bills have been introduced but not passed.

Maryland: An attorney general announcement of $42 million for ibogaine addiction research has been reported. The state has pursued research-focused psychedelic policy.

Utah: A Task Force on Responsible Use of Natural Psychedelic Substances has been approved and is operating.

Virginia, Illinois, North Carolina, New York, Pennsylvania, Georgia: All have had psychedelic reform legislation introduced in recent sessions covering research authorization, therapeutic access programs, or decriminalization. None have enacted statewide reform as of early 2026.

States with no statewide or city-level reform

As of early 2026, the following states have no enacted decriminalization, no licensed program, no formally operational research commission specifically on psilocybin, and no local city measures: Alabama, Arkansas, Delaware, Florida, Idaho, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, North Dakota, Ohio, Oklahoma, Rhode Island, South Carolina, South Dakota, Tennessee, West Virginia, Wisconsin, Wyoming.

In all of these states, psilocybin possession, manufacture, and distribution are criminal offenses under state law, in addition to being federal crimes.

What is the same across all states

Federal law applies everywhere. Psilocybin is Schedule I under the Controlled Substances Act in every state, including Oregon, Colorado, and New Mexico. State programs do not provide federal legal protection.

Commercial sale is not authorized anywhere outside a licensed program. Even in cities with decriminalization measures, selling psilocybin is a crime.

No state allows doctors to prescribe psilocybin. Oregon and Colorado operate through a facilitator-based model, not a prescription model. New Mexico operates through licensed healthcare providers, but “prescribing” is not the right word — the provider oversees administration in an approved setting.

Crossing state lines with psilocybin is a federal crime regardless of origin or destination state. Transporting a Schedule I substance in interstate commerce is a federal offense.

You might also want to read

This article is public legal education, not legal advice. Laws in this area change frequently. Verify current status in your jurisdiction before making any decisions. If your situation is specific, speak with a lawyer who practices in this area.